Compare Citius Pharmaceuticals Inc (CTXR) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Clear Secure Inc trades at $43.54 (market cap $4.44B). The key difference: Clear Secure Inc is far larger — about 326× Citius Pharmaceuticals Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Clear Secure Inc for 19 Days on average.
| CTXR | YOU | |
|---|---|---|
Market Cap | $13.62M | $4.44B |
Volume | 132,438 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $1.82 | $62.36 |
52-Week Low | $0.48 | $29.61 |
Typical Hold Time | 16 Days | 19 Days |
Enterprise Value | $3.79M | $3.59B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Clear Secure (YOU) trades at $42.58, up 2.6% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 27% revenue growth in Q2 2026, beating earnings estimates, and robust profitability metrics including 66.7% gross margin and 90.3% ROE. Recent partnership with CrowdStrike and corporate membership launch highlight growth initiatives.
The stock offers 44% upside to the $61.40 consensus target with analyst sentiment divided equally between Buy and Hold. Key risks include competitive pressures and execution of expansion plans. Strong cash flow generation and accelerating membership growth support the bullish case, though valuation multiples remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
